Loading companies…
CT
Connecta Therapeutics
Spain · Biotech
Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.
Product and development
Connecta Therapeutics is developing CTH120, a small-molecule neuroplasticity modulator intended as a potential disease-modifying treatment for Fragile X syndrome. The candidate is being evaluated in an ongoing Phase IIa clinical trial in adult men, with the study assessing safety, tolerability and effectiveness.
The company’s work is aimed at patients with Fragile X syndrome and the clinicians who treat them. Connecta is preparing further pediatric development; CTH120 remains an investigational medicine, and the company’s September financing is intended to support the ongoing clinical program.
- Product focus
- CTH120 clinical program for Fragile X syndrome
Funding history
0 rounds · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|
Investors
No participants disclosed.
Coverage
Similar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed